Atorvastatin市場：按適應症分類 - 2025-2030 年全球預測

2023年Atorvastatin市場估值為12.6億美元，預計2024年將達到13.2億美元，複合年成長率為5.17%，預計2030年將達到18億美元。

Atorvastatin是一種廣泛用於控制膽固醇水平和預防心血管疾病的他汀類藥物，在藥物製造、醫療和患者照護領域擁有全球市場。對Atorvastatin的需求源於其已被證明可有效降低低密度脂蛋白 (LDL) 膽固醇並降低心臟病發作和中風相關的風險。其用途不僅限於治療高膽固醇症，也擴及預防混合型血脂異常和高危險群。最終用途主要包括醫院、診所和門診診所，隨著患者轉向獨立的慢性病管理，家庭護理的趨勢日益成長。影響該市場的主要成長要素包括全球心血管疾病盛行率的增加、人口老化以及對預防性醫療保健的日益關注。學名藥的進入和消費者健康意識的提高帶來了潛在的商機。公司可以透過強調可負擔性、宣傳Atorvastatin適應症的更廣泛益處以及擴大其在醫療保健可及性不斷改善的新興市場的影響力來利用這些優勢。然而，市場成長受到諸如嚴格的監管核准流程、導致患者違規的副作用以及來自品牌藥和學名藥的競爭等挑戰的阻礙。創新領域包括開發提高患者依從性的聯合治療、先進的藥物傳輸系統以及整合遠端醫療平台和藥物管理的數位健康解決方案。探索針對基因譜量身定做的個人化醫療方法也可能提供重要的業務成長途徑。在持續的產品開發和醫療進步的推動下，Atorvastatin市場的競爭非常激烈，因此為了保持競爭力，公司必須保持敏捷並採用技術主導的解決方案，而建立策略夥伴關係至關重要。

市場動態：揭示快速發展的Atorvastatin市場的關鍵市場洞察

Atorvastatin市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

• 市場促進因素
  • 全球心血管疾病盛行率不斷上升
  • 醫改推廣預防醫學
• 市場限制因素
  • 產品召回及其對品牌聲譽的影響
• 市場機會
  • 政府和監管機構對心血管研究的支持
  • Atorvastatin有效治療策略夥伴關係
• 市場問題
  • 他汀類替代藥物的可用性

波特五力：駕馭Atorvastatin市場的策略工具

波特的五力框架是了解Atorvastatin市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解Atorvastatin市場的外部影響

外部宏觀環境因素在塑造Atorvastatin市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解Atorvastatin市場的競爭格局

對Atorvastatin市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：Atorvastatin市場供應商的績效評估

FPNV定位矩陣是評估Atorvastatin市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：規劃Atorvastatin市場的成功之路

對於旨在加強其全球市場影響力的公司來說，Atorvastatin市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

• 市場動態
  • 促進因素
    • 全球心血管疾病盛行率不斷上升
    • 醫改推廣預防醫學
  • 抑制因素
    • 產品召回及其對品牌聲譽的影響
  • 機會
    • 政府和監管機構對心血管研究的支持
    • 有效Atorvastatin治療方法的策略合作
  • 任務
    • 他汀類替代藥物的可用性
• 市場區隔分析
  • 適應症：由於飲食習慣、遺傳和其他健康狀況導致高高膽固醇症盛行率增加
• 波特五力分析
• PESTEL分析
  • 政治
  • 經濟
  • 社會
  • 科技
  • 法律
  • 環境

第6章Atorvastatin市場：依適應症分類

• 介紹
• 血脂異常症
• 高膽固醇症
• 高三酸甘油脂血症

第7章 美洲Atorvastatin市場

• 介紹
• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第8章亞太阿托Atorvastatin市場

• 介紹
• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第9章歐洲、中東和非洲Atorvastatin市場

• 介紹
• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第10章競爭格局

• 2023 年市場佔有率分析
• FPNV 定位矩陣，2023
• 競爭情境分析
  • FDA核准擴大 Esperion 心血管藥物 Nexletor 和 Nexlisette 的使用
  • 歐洲健康委員會重新核准降膽固醇藥物
  • NHLBI 向德州心臟研究所津貼114 萬美元，用於創新心血管疾病治療
• 戰略分析和建議

公司名單

• Accord Healthcare, Inc.
• AdvaCare Pharma USA
• Anant Pharmaceuticals Pvt. Ltd.
• Apotex Inc.
• Centrient Pharmaceuticals
• Cerata Pharmaceuticals LLP
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Fengchen Group Co.,Ltd
• Hangzhou Jeci Biochem Technology Co.,Ltd.
• Hunan Huateng Pharmaceutical Co., Ltd
• Lupin Limited
• Manus Aktteva Biopharma LLP
• Merck KGaA
• Morepen Laboratories Limited
• Novartis AG
• Pfizer Inc.
• Ranbaxy Laboratories Ltd. by Sun Pharmaceutical Industries Ltd.
• SAIN Medicaments Pvt. Ltd.
• Taj Pharmaceuticals Limited
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
• Torrent Pharmaceuticals Ltd.
• Viatris Inc.
• Zydus Lifesciences Limited

The Atorvastatin Market was valued at USD 1.26 billion in 2023, expected to reach USD 1.32 billion in 2024, and is projected to grow at a CAGR of 5.17%, to USD 1.80 billion by 2030.

Atorvastatin, a widely prescribed statin used for managing cholesterol levels and preventing cardiovascular disease, has a global market scope that extends across pharmaceutical manufacturing, healthcare, and patient care sectors. The necessity of atorvastatin arises from its proven efficacy in reducing low-density lipoprotein (LDL) cholesterol and thereby mitigating risks associated with heart attacks and strokes. Its application is not limited to therapy for hypercholesterolemia but also extends to cases of mixed dyslipidemia and prevention for at-risk populations. The end-use scope primarily includes hospitals, clinics, and outpatient services, with a growing trend in home-care settings as patients increasingly manage chronic conditions independently. Key growth factors influencing this market include the increasing prevalence of cardiovascular diseases globally, aging populations, and the rising focus on preventive healthcare. The entry of generic versions and the increasing health awareness among consumers present potential opportunities. Companies can capitalize on these by emphasizing affordability, promoting atorvastatin's extensive benefits, and expanding presence in emerging markets where healthcare access is improving. However, market growth is hampered by challenges such as stringent regulatory approval processes, side effect profiles leading to patient non-compliance, and competition from both branded drugs and generics. Innovation areas include the development of combination therapies that enhance patient adherence, advanced drug delivery systems, and digital health solutions that integrate medication management with telemedicine platforms. Research into personalized medicine approaches tailored to genetic profiles could also offer significant business growth avenues. The nature of the atorvastatin market is highly competitive, driven by continuous product development and healthcare advancements, making it crucial for businesses to stay agile, adopting tech-driven solutions and forging strategic partnerships to maintain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Atorvastatin Market

The Atorvastatin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing global prevalence of cardiovascular diseases
  • Healthcare reforms promoting preventive care
• Market Restraints
  • Product recalls and impact on brand reputation
• Market Opportunities
  • Government and regulatory support for cardiovascular research
  • Strategic collaboration for effective atorvastatin based therapeutics
• Market Challenges
  • Availability of alternative statin drugs

Porter's Five Forces: A Strategic Tool for Navigating the Atorvastatin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Atorvastatin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Atorvastatin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Atorvastatin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Atorvastatin Market

A detailed market share analysis in the Atorvastatin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Atorvastatin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Atorvastatin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Atorvastatin Market

A strategic analysis of the Atorvastatin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Atorvastatin Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare, Inc., AdvaCare Pharma USA, Anant Pharmaceuticals Pvt. Ltd., Apotex Inc., Centrient Pharmaceuticals, Cerata Pharmaceuticals LLP, Cipla Limited, Dr. Reddy's Laboratories Ltd., Fengchen Group Co.,Ltd, Hangzhou Jeci Biochem Technology Co.,Ltd., Hunan Huateng Pharmaceutical Co., Ltd, Lupin Limited, Manus Aktteva Biopharma LLP, Merck KGaA, Morepen Laboratories Limited, Novartis AG, Pfizer Inc., Ranbaxy Laboratories Ltd. by Sun Pharmaceutical Industries Ltd., SAIN Medicaments Pvt. Ltd., Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Torrent Pharmaceuticals Ltd., Viatris Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Atorvastatin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Indications, market is studied across Dyslipidemia, Hypercholesterolemia, and Hypertriglyceridemia.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing global prevalence of cardiovascular diseases
    • 5.1.1.2. Healthcare reforms promoting preventive care
  • 5.1.2. Restraints
    • 5.1.2.1. Product recalls and impact on brand reputation
  • 5.1.3. Opportunities
    • 5.1.3.1. Government and regulatory support for cardiovascular research
    • 5.1.3.2. Strategic collaboration for effective atorvastatin based therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of alternative statin drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Indication: Increasing prevalence hypercholesterolemia of owing to dietary habits, genetics, or other health conditions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Atorvastatin Market, by Indications

• 6.1. Introduction
• 6.2. Dyslipidemia
• 6.3. Hypercholesterolemia
• 6.4. Hypertriglyceridemia

7. Americas Atorvastatin Market

• 7.1. Introduction
• 7.2. Argentina
• 7.3. Brazil
• 7.4. Canada
• 7.5. Mexico
• 7.6. United States

8. Asia-Pacific Atorvastatin Market

• 8.1. Introduction
• 8.2. Australia
• 8.3. China
• 8.4. India
• 8.5. Indonesia
• 8.6. Japan
• 8.7. Malaysia
• 8.8. Philippines
• 8.9. Singapore
• 8.10. South Korea
• 8.11. Taiwan
• 8.12. Thailand
• 8.13. Vietnam

9. Europe, Middle East & Africa Atorvastatin Market

• 9.1. Introduction
• 9.2. Denmark
• 9.3. Egypt
• 9.4. Finland
• 9.5. France
• 9.6. Germany
• 9.7. Israel
• 9.8. Italy
• 9.9. Netherlands
• 9.10. Nigeria
• 9.11. Norway
• 9.12. Poland
• 9.13. Qatar
• 9.14. Russia
• 9.15. Saudi Arabia
• 9.16. South Africa
• 9.17. Spain
• 9.18. Sweden
• 9.19. Switzerland
• 9.20. Turkey
• 9.21. United Arab Emirates
• 9.22. United Kingdom

10. Competitive Landscape

• 10.1. Market Share Analysis, 2023
• 10.2. FPNV Positioning Matrix, 2023
• 10.3. Competitive Scenario Analysis
  • 10.3.1. FDA Approves Expanded Use of Esperion's Cardiovascular Drugs Nexletol and Nexlizet
  • 10.3.2. Updated Approval for Cholesterol-Reducing Medications by European Health Committee
  • 10.3.3. Innovative Cardiovascular Disease Treatment on the Horizon with USD 1.14 Million NHLBI Grant to Texas Heart Institute
• 10.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Accord Healthcare, Inc.
• 2. AdvaCare Pharma USA
• 3. Anant Pharmaceuticals Pvt. Ltd.
• 4. Apotex Inc.
• 5. Centrient Pharmaceuticals
• 6. Cerata Pharmaceuticals LLP
• 7. Cipla Limited
• 8. Dr. Reddy's Laboratories Ltd.
• 9. Fengchen Group Co.,Ltd
• 10. Hangzhou Jeci Biochem Technology Co.,Ltd.
• 11. Hunan Huateng Pharmaceutical Co., Ltd
• 12. Lupin Limited
• 13. Manus Aktteva Biopharma LLP
• 14. Merck KGaA
• 15. Morepen Laboratories Limited
• 16. Novartis AG
• 17. Pfizer Inc.
• 18. Ranbaxy Laboratories Ltd. by Sun Pharmaceutical Industries Ltd.
• 19. SAIN Medicaments Pvt. Ltd.
• 20. Taj Pharmaceuticals Limited
• 21. Teva Pharmaceutical Industries Ltd.
• 22. Thermo Fisher Scientific Inc.
• 23. Torrent Pharmaceuticals Ltd.
• 24. Viatris Inc.
• 25. Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. ATORVASTATIN MARKET RESEARCH PROCESS
• FIGURE 2. ATORVASTATIN MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ATORVASTATIN MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ATORVASTATIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. AMERICAS ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 9. AMERICAS ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. UNITED STATES ATORVASTATIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 11. UNITED STATES ATORVASTATIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. ASIA-PACIFIC ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ATORVASTATIN MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 17. ATORVASTATIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ATORVASTATIN MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ATORVASTATIN MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ATORVASTATIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ATORVASTATIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ATORVASTATIN MARKET DYNAMICS
• TABLE 7. GLOBAL ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ATORVASTATIN MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ATORVASTATIN MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ATORVASTATIN MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. AMERICAS ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 12. AMERICAS ATORVASTATIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 13. ARGENTINA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 14. BRAZIL ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 15. CANADA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 16. MEXICO ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 17. UNITED STATES ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 18. UNITED STATES ATORVASTATIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 19. ASIA-PACIFIC ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 20. ASIA-PACIFIC ATORVASTATIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. AUSTRALIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 22. CHINA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 23. INDIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 24. INDONESIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 25. JAPAN ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 26. MALAYSIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 27. PHILIPPINES ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 28. SINGAPORE ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 29. SOUTH KOREA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 30. TAIWAN ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 31. THAILAND ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 32. VIETNAM ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 33. EUROPE, MIDDLE EAST & AFRICA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 34. EUROPE, MIDDLE EAST & AFRICA ATORVASTATIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. DENMARK ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 36. EGYPT ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 37. FINLAND ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 38. FRANCE ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 39. GERMANY ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 40. ISRAEL ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 41. ITALY ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 42. NETHERLANDS ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 43. NIGERIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 44. NORWAY ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 45. POLAND ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 46. QATAR ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 47. RUSSIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 48. SAUDI ARABIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH AFRICA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 50. SPAIN ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 51. SWEDEN ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 52. SWITZERLAND ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 53. TURKEY ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 54. UNITED ARAB EMIRATES ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED KINGDOM ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 56. ATORVASTATIN MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 57. ATORVASTATIN MARKET, FPNV POSITIONING MATRIX, 2023